publication date: Oct. 5, 2018

Guest Editorial Thank you, Jim Allison Ronald DePinho

By Ronald A. DePinho

Professor & past president,

Harry Graves Burkhart III Distinguished University Chair,

Department of Cancer Biology, MD Anderson Cancer Center

 

The year was 1998, location, Italian Alps. Jim and I were attending an intimate Pezcoller meeting organized by David Livingston. At that meeting, Jim presented something I had never seen in the entirety of my career—the eradication of cancer in mice following treatment with an antibody designed to inhibit a T cell checkpoint mechanism.

Afterwards, we talked about his provocative science and the potential of a new class of cancer drugs. As a physician scientist, I can vividly recall how deeply impressed I was with Jim’s intense passion to convert his science into a new medicine that could help cancer patients.

Years later, I learned that his intense drive for clinical impact was fueled by the loss of his mother when he was only 10 years old.

It took another 10 years for Jim’s dream to be realized. His drug for melanoma was approved, and early stage clinical trials … Continue reading Thank you, Jim Allison

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.